Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety
and efficacy of AT-001 in adult patients (N=675) with Diabetic Cardiomyopathy at high risk of
progression to overt heart failure.